Swiss National Bank
KROS icon

Swiss National Bank’s Keros Therapeutics KROS Stock Holding History

Swiss National Bank’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59,000
Closed -$934K – 2424
2024
Q4 		$934K Buy
59,000
+2,700
+5% +$140K ﹤0.01% 2228
2024
Q3 		$3.27M Sell
56,300
-500
-0.9% -$24.7K ﹤0.01% 1573
2024
Q2 		$2.6M Buy
56,800
+6,900
+14% +$371K ﹤0.01% 1678
2024
Q1 		$3.3M Buy
49,900
+9,000
+22% +$534K ﹤0.01% 1561
2023
Q4 		$1.63M Sell
40,900
-4,700
-10% -$147K ﹤0.01% 1968
2023
Q3 		$1.45M Buy
45,600
+2,100
+5% +$78.4K ﹤0.01% 2030
2023
Q2 		$1.75M Buy
43,500
+7,800
+22% +$342K ﹤0.01% 1973
2023
Q1 		$1.52M Sell
35,700
-1,600
-4% -$80.8K ﹤0.01% 2009
2022
Q4 		$1.79M Buy
37,300
+3,100
+9% +$145K ﹤0.01% 1957
2022
Q3 		$1.29M Buy
34,200
+1,100
+3% +$38.1K ﹤0.01% 2181
2022
Q2 		$915K Buy
33,100
+2,700
+9% +$118K ﹤0.01% 2416
2022
Q1 		$1.65M Buy
30,400
+2,300
+8% +$118K ﹤0.01% 2138
2021
Q4 		$1.64M Hold
28,100
– – ﹤0.01% 2185
2021
Q3 		$1.11M Hold
28,100
– – ﹤0.01% 2383
2021
Q2 		$1.19M Buy
28,100
+7,500
+36% +$406K ﹤0.01% 2402
2021
Q1 		$1.27M Hold
20,600
– – ﹤0.01% 2259
2020
Q4 		$1.45M Buy
+20,600
New +$1.3M ﹤0.01% 2095

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Swiss National Bank's KROS Position: Q1 2025 in Review

Swiss National Bank sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 59,000 shares — an estimated $934K sold.

Swiss National Bank first reported a position in KROS in Q4 2020 and held it in 17 quarters. The position peaked at $3.3M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Swiss National Bank reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 59,000 Keros Therapeutics shares in Q1 2025, an estimated $934K.
  • Swiss National Bank first reported a position in Keros Therapeutics in Q4 2020 and held it in 17 quarters.
  • Swiss National Bank's Keros Therapeutics position peaked at $3.3M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.